Pu Chun-Lin, Li Jiu-Zhi, Fan Wen-Long
Department of Urology Center, People's Hospital of Xinjiang Uygur Antonomous Region.
Department of Urology Center, Xinjiang Medical University, Urumqi, Xinjiang, China.
Medicine (Baltimore). 2020 May 22;99(21):e20297. doi: 10.1097/MD.0000000000020297.
A numerous published studies have reported that docetaxel combined carboplatin (DC) has been utilized for the treatment of patients with castration-resistant prostate cancer (CRPC). However, there are still contradictory results. Therefore, this systematic review and meta-analysis will explore the efficacy and safety of DC for the treatment of patients with CRPC.
We will systematically and comprehensively search MEDLINE, EMBASE, Cochrane Library, Web of Science, CINAHL, WANGFANG, CBM, and CNKI from the beginning up to the March 1, 2020, regardless language and publication time. We will consider randomized controlled trials that evaluated the efficacy and safety of DC for the treatment of patients with CRPC. The treatment effects of all dichotomous data will be estimated as risk ratio and 95% confidence intervals (CIs), and that of continuous outcomes will be calculated as standardized mean difference or mean difference and 95% CIs. Methodological quality will be appraised by Cochrane risk of bias tool, and quality of evidence will be identified by Grading of Recommendations Assessment Development and Evaluation. Statistical analysis will be undertaken by RevMan 5.3 software.
This study will systematically explore the efficacy and safety of DC for the treatment of patients with CRPC.
This study may provide helpful evidence to determine whether DC is an effective treatment for patients with CRPC or not.
INPLASY202040076.
大量已发表的研究报告称，多西他赛联合卡铂（DC）已被用于治疗去势抵抗性前列腺癌（CRPC）患者。然而，仍有相互矛盾的结果。因此，本系统评价和荟萃分析将探讨DC治疗CRPC患者的疗效和安全性。
我们将系统全面地检索MEDLINE、EMBASE、Cochrane图书馆、科学网、CINAHL、万方、中国生物医学文献数据库和中国知网，检索时间从建库至2020年3月1日，不限语言和发表时间。我们将纳入评估DC治疗CRPC患者疗效和安全性的随机对照试验。所有二分数据的治疗效果将以风险比和95%置信区间（CI）进行估计，连续结果的治疗效果将计算标准化均数差或均数差及95%CI。方法学质量将采用Cochrane偏倚风险工具进行评估，证据质量将通过推荐分级评估、制定与评价进行确定。统计分析将采用RevMan 5.3软件进行。
本研究将系统探讨DC治疗CRPC患者的疗效和安全性。
本研究可能为确定DC是否为CRPC患者的有效治疗方法提供有用证据。
INPLASY202040076。
